CorMedix (CRMD) Interest & Investment Income (2010 - 2025)
CorMedix (CRMD) posted Interest & Investment Income of $3.8 million for Q4 2025, up 46890.59% sequentially from $8181.0 in Q3 2025, and up 48.84% YoY from $2.6 million in Q4 2024.
CorMedix (CRMD) Interest & Investment Income (2010 - 2025) Analysis & Trends
CorMedix has reported Interest & Investment Income for 15 years, with the latest figure at $3.8 million in Q4 2025.
- Quarterly Interest & Investment Income rose 48.84% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 11.57% YoY) and the FY2025 annual result came in at $3.8 million, up 49.13% from the prior year.
- Interest & Investment Income climbed to $3.8 million in Q4 2025 per CRMD's latest filing, from $8181.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $3.8 million in Q4 2025 and troughed at -$10732.0 in Q2 2023.
- A 5-year average of $571877.7 and a median of $10966.0 in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 4739.93% in 2023, then tumbled 197.09% in 2025.
- Over 5 years, Interest & Investment Income stood at $4367.0 in 2021, then soared by 4102.08% to $183505.0 in 2022, then soared by 1360.87% to $2.7 million in 2023, then dropped by 3.65% to $2.6 million in 2024, then soared by 48.84% to $3.8 million in 2025.
- According to Business Quant data, Interest & Investment Income over the past three periods registered $3.8 million, $8181.0, and -$1971.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 8,181.00 |
| Jun 30, 2025 | -1,971.00 |
| Mar 31, 2025 | -4,511.00 |
| Dec 31, 2024 | 2.58 Mn |
| Sep 30, 2024 | 5,040.00 |
| Jun 30, 2024 | 2,030.00 |
| Mar 31, 2024 | 857,186.00 |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 765,241.00 |
| Jun 30, 2023 | -10,732.00 |
| Mar 31, 2023 | 446,384.00 |
| Dec 31, 2022 | 183,505.00 |
| Sep 30, 2022 | 15,811.00 |
| Jun 30, 2022 | 35,342.00 |
| Mar 31, 2022 | 13,751.00 |
| Dec 31, 2021 | 4,367.00 |
| Sep 30, 2021 | 3,022.00 |
| Jun 30, 2021 | 3,340.00 |
| Mar 31, 2021 | 3,675.00 |